全文获取类型
收费全文 | 8633篇 |
免费 | 628篇 |
国内免费 | 23篇 |
专业分类
耳鼻咽喉 | 42篇 |
儿科学 | 251篇 |
妇产科学 | 248篇 |
基础医学 | 1314篇 |
口腔科学 | 181篇 |
临床医学 | 1011篇 |
内科学 | 1656篇 |
皮肤病学 | 240篇 |
神经病学 | 1150篇 |
特种医学 | 217篇 |
外科学 | 702篇 |
综合类 | 67篇 |
一般理论 | 9篇 |
预防医学 | 787篇 |
眼科学 | 300篇 |
药学 | 529篇 |
中国医学 | 20篇 |
肿瘤学 | 560篇 |
出版年
2023年 | 74篇 |
2022年 | 97篇 |
2021年 | 205篇 |
2020年 | 185篇 |
2019年 | 215篇 |
2018年 | 271篇 |
2017年 | 212篇 |
2016年 | 222篇 |
2015年 | 270篇 |
2014年 | 300篇 |
2013年 | 456篇 |
2012年 | 733篇 |
2011年 | 718篇 |
2010年 | 374篇 |
2009年 | 341篇 |
2008年 | 641篇 |
2007年 | 590篇 |
2006年 | 548篇 |
2005年 | 518篇 |
2004年 | 480篇 |
2003年 | 446篇 |
2002年 | 434篇 |
2001年 | 63篇 |
2000年 | 39篇 |
1999年 | 61篇 |
1998年 | 83篇 |
1997年 | 72篇 |
1996年 | 66篇 |
1995年 | 45篇 |
1994年 | 50篇 |
1993年 | 41篇 |
1992年 | 28篇 |
1991年 | 23篇 |
1990年 | 17篇 |
1989年 | 17篇 |
1988年 | 16篇 |
1987年 | 20篇 |
1986年 | 20篇 |
1985年 | 17篇 |
1984年 | 21篇 |
1983年 | 16篇 |
1982年 | 23篇 |
1980年 | 16篇 |
1978年 | 22篇 |
1977年 | 14篇 |
1976年 | 12篇 |
1975年 | 12篇 |
1971年 | 12篇 |
1970年 | 10篇 |
1968年 | 10篇 |
排序方式: 共有9284条查询结果,搜索用时 15 毫秒
141.
142.
143.
Carlos A. Jiménez Ruiz Daniel Buljubasich Juan Antonio Riesco Miranda Agustín Acuña Izcaray José Ignacio de Granda Orive José Miguel Chatkin Gustavo Zabert Alfredo Guerreros Benavides Nelson Paez Espinel Valeri Noé Efraín Sánchez-Angarita Ingrid Núñez-Sánchez Raúl H. Sansores Alejandro Casas Andrés Palomar Lever Inmaculada Alfageme Michavila 《Archivos de bronconeumología》2017,53(11):622-628
The ALAT and SEPAR Treatment and Control of Smoking Groups have collaborated in the preparation of this document which attempts to answer, by way of PICO methodology, different questions on health interventions for helping COPD patients to stop smoking.The main recommendations are: (i) moderate-quality evidence and strong recommendation for performing spirometry in COPD patients and in smokers with a high risk of developing the disease, as a motivational tool (particularly for showing evidence of lung age), a diagnostic tool, and for active case-finding; (ii) high-quality evidence and strong recommendation for using intensive dedicated behavioral counselling and drug treatment for helping COPD patients to stop smoking; (iii) high-quality evidence and strong recommendation for initiating interventions for helping COPD patients to stop smoking during hospitalization with improvement when the intervention is prolonged after discharge, and (iv) high-quality evidence and strong recommendation for funding treatment of smoking in COPD patients, in view of the impact on health and health economics. 相似文献
144.
145.
Xavier Pichon Anne S Wattiez Carine Becamel Ingrid Ehrlich Joel Bockaert Alain Eschalier Philippe Marin Christine Courteix 《Molecular therapy》2010,18(8):1462-1470
Antidepressants are one of the first-line treatments for neuropathic pain. Despite the influence of serotonin (5-hydroxytryptamine, 5-HT) in pain modulation, selective serotonin reuptake inhibitors (SSRIs) are less effective than tricyclic antidepressants. Here, we show, in diabetic neuropathic rats, an alteration of the antihyperalgesic effect induced by stimulation of 5-HT2A receptors, which are known to mediate SSRI-induced analgesia. 5-HT2A receptor density was not changed in the spinal cord of diabetic rats, whereas postsynaptic density protein-95 (PSD-95), one of the PSD-95/disc large suppressor/zonula occludens-1 (PDZ) domain containing proteins interacting with these receptors, was upregulated. Intrathecal injection of a cell-penetrating peptidyl mimetic of the 5-HT2A receptor C-terminus, which disrupts 5-HT2A receptor–PDZ protein interactions, induced an antihyperalgesic effect in diabetic rats, which results from activation of 5-HT2A receptors by endogenous 5-HT. The peptide also enhanced antihyperalgesia induced by the SSRI fluoxetine. Its effects likely resulted from an increase in receptor responsiveness, because it revealed functional 5-HT2A receptor-operated Ca2+ responses in neurons, an effect mimicked by knockdown of PSD-95. Hence, 5-HT2A receptor/PDZ protein interactions might contribute to the resistance to SSRI-induced analgesia in painful diabetic neuropathy. Disruption of these interactions might be a valuable strategy to design novel treatments for neuropathic pain and to increase the effectiveness of SSRIs. 相似文献
146.
Saelen MG Prøsch LK Gudmundsdottir H Dyrbekk D Helge Hunderi O Arnesen E Paulsen D Skjønsberg H Os I 《Blood pressure》2005,14(3):170-176
This study compared the use of antihypertensive treatment and blood pressure (BP) controls between patients with diabetic kidney disease (DK+) and patients with non-diabetic kidney disease (DK-) exhibiting moderate-to-severe chronic renal failure who did not need renal replacement therapy. A cross-sectional survey included all renal patients with s-creatinine at ?200 micromol/l attending regular control sessions at six renal units in Norway. Of the 351 patients included, 73 (20.8%) were DK+. The proportion reaching a BP goal of <130/80 mmHg was similar in DK+ and DK- (14.1% vs 13.6%, p = 0.92), while 38% and 39% achieved a BP of <140/90 mmHg, respectively. The systolic BP goal was more difficult to achieve than the diastolic BP goal in DK+ patients (35% vs 15%) despite a mean of three different types of drugs being used. Loop diuretics and beta-adrenergic-receptor antagonists were the most frequently prescribed drugs, and the use of angiotensin-converting enzyme inhibitors or angiotensin-II-receptor antagonists declined when renal function deteriorated, from 80% to 0% and from 66% to 20% in the DK+ and DK- groups, respectively (p = 0.001). Thus, despite the use of multiple antihypertensive drugs, controlling BP - especially the systolic BP - is difficult in high-risk patients with chronic renal failure caused by diabetic kidney disease. 相似文献
147.
Tai YT Dillon M Song W Leiba M Li XF Burger P Lee AI Podar K Hideshima T Rice AG van Abbema A Jesaitis L Caras I Law D Weller E Xie W Richardson P Munshi NC Mathiot C Avet-Loiseau H Afar DE Anderson KC 《Blood》2008,112(4):1329-1337
Currently, no approved monoclonal antibody (mAb) therapies exist for human multiple myeloma (MM). Here we characterized cell surface CS1 as a novel MM antigen and further investigated the potential therapeutic utility of HuLuc63, a humanized anti-CS1 mAb, for treating human MM. CS1 mRNA and protein was highly expressed in CD138-purified primary tumor cells from the majority of MM patients (more than 97%) with low levels of circulating CS1 detectable in MM patient sera, but not in healthy donors. CS1 was expressed at adhesion-promoting uropod membranes of polarized MM cells, and short interfering RNA (siRNA) targeted to CS1 inhibited MM cell adhesion to bone marrow stromal cells (BMSCs). HuLuc63 inhibited MM cell binding to BMSCs and induced antibody-dependent cellular cytotoxicity (ADCC) against MM cells in dose-dependent and CS1-specific manners. HuLuc63 triggered autologous ADCC against primary MM cells resistant to conventional or novel therapies, including bortezomib and HSP90 inhibitor; and pretreatment with conventional or novel anti-MM drugs markedly enhanced HuLuc63-induced MM cell lysis. Administration of HuLuc63 significantly induces tumor regression in multiple xenograft models of human MM. These results thus define the functional significance of CS1 in MM and provide the preclinical rationale for testing HuLuc63 in clinical trials, either alone or in combination. 相似文献
148.
OBJECTIVE: To evaluate the validity, responsiveness, and predictive value of power Doppler ultrasonography (PDUS) monitoring of response to tumor necrosis factor (TNF) blocking agents in rheumatoid arthritis (RA). METHODS: Three hundred sixty-seven RA patients were prospectively recruited at 25 Spanish centers; complete clinical, laboratory, and PDUS data were obtained on 278 patients. The patients underwent clinical, laboratory, and PDUS assessment at baseline and after 1, 3, 6, and 12 months of anti-TNF treatment, and radiographic assessment of the hands and feet at baseline and 12 months. The Disease Activity Score in 28 joints (DAS28) was recorded at each visit. PDUS examination included 86 intraarticular and periarticular sites in 28 joints. US synovial fluid (SF), synovial hypertrophy (SH), and PD signal were scored in all synovial sites. US count and index for SF, SH, and PD signal were obtained. Sensitivity to change of the PDUS variables was assessed by estimating the smallest detectable difference (SDD) from the intraobserver variability. RESULTS: A significant parallel improvement in DAS28 and PDUS parameters was found at followup assessment (P < 0.0005 for within-subject between-visit changes). The SDD for PDUS parameters was lower than the mean changes throughout followup. Time-integrated values of US joint count for PD signal and rheumatoid factor (RF) showed predictive value in relation to progression of radiographic erosion (R = 0.64), and time-integrated values of US joint count for PD signal, RF, and erythrocyte sedimentation rate were predictors of progression of the total radiographic score (R = 0.59). CONCLUSION: These findings indicate that PDUS is a valid method for monitoring response to anti-TNF therapy in RA; results obtained by PDUS are reproducible and sensitive to change. PDUS findings may have predictive value in relation to radiologic outcome. 相似文献
149.
Somatically mutated Ig V(H)3-21 genes characterize a new subset of chronic lymphocytic leukemia 总被引:5,自引:16,他引:5 下载免费PDF全文
Tobin G Thunberg U Johnson A Thörn I Söderberg O Hultdin M Botling J Enblad G Sällström J Sundström C Roos G Rosenquist R 《Blood》2002,99(6):2262-2264
Recent studies on the immunoglobulin variable heavy chain (IgV(H)) genes have revealed that B-cell chronic lymphocytic leukemia (B-CLL) consists of at least 2 clinical entities with either somatically mutated or unmutated V(H) genes. We have analyzed the V(H) gene mutation status and V(H) gene usage in 119 B-CLL cases and correlated them to overall survival. A novel finding was the preferential use of the V(H)3-21 gene in mutated cases, whereas biased V(H)1-69 gene usage was found in unmutated cases as previously reported. Interestingly, the subset of mutated cases using the V(H)3-21 gene displayed distinctive genotypic/phenotypic characteristics with shorter average length of the complementarity determining region 3 and clonal expression of lambda light chains. In addition, this mutated subset showed significantly shorter survival than other mutated cases and a similar clinical course to unmutated cases. We therefore suggest that B-CLL cases with mutated V(H)3-21 genes may constitute an additional entity of B-CLL. 相似文献
150.
Dixit M Loot AE Mohamed A Fisslthaler B Boulanger CM Ceacareanu B Hassid A Busse R Fleming I 《Circulation research》2005,97(12):1236-1244
Fluid shear stress enhances NO production in endothelial cells by a mechanism involving the activation of the phosphatidylinositol 3-kinase and the phosphorylation of the endothelial NO synthase (eNOS). We investigated the role of the scaffolding protein Gab1 and the tyrosine phosphatase SHP2 in this signal transduction cascade in cultured and native endothelial cells. Fluid shear stress elicited the phosphorylation and activation of Akt and eNOS as well as the tyrosine phosphorylation of Gab1 and its association with the p85 subunit of phosphatidylinositol 3-kinase and SHP2. Overexpression of a Gab1 mutant lacking the pleckstrin homology domain abrogated the shear stress-induced phosphorylation of Akt but failed to affect the phosphorylation or activity of eNOS. The latter response, however, was sensitive to a protein kinase A (PKA) inhibitor. Mutation of Gab1 Tyr627 to phenylalanine (YF-Gab1) to prevent the binding of SHP2 completely prevented the shear stress-induced phosphorylation of eNOS, leaving the Akt response intact. A dominant-negative SHP2 mutant prevented the activation of PKA and phosphorylation of eNOS without affecting that of Akt. Moreover, shear stress elicited the formation of a signalosome complex including eNOS, Gab1, SHP2 and the catalytic subunit of PKA. In isolated murine carotid arteries, flow-induced vasodilatation was prevented by a PKA inhibitor as well as by overexpression of either the YF-Gab1 or the dominant-negative SHP2 mutant. Thus, the shear stress-induced activation of eNOS depends on Gab1 and SHP2, which, in turn, regulate the phosphorylation and activity of eNOS by a PKA-dependent but Akt-independent mechanism. 相似文献